In summary, our results provide a mechanistic basis for the combination of CDK7 inhibitors and standard chemotherapy in the treatment of pancreatic cancer, and support the application of CRISPR-Cas9 functional genomics in the identification of novel therapeutic targets and the development of new targeted drugs to increase the efficacy of chemotherapies. This evidence concerns the gene CDK7 and pancreatic neoplasm.